Guangzhou LBP Medicine Science & Technology Co., Ltd (SHA: 688393), a biopharmaceutical company based in China, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its HER2 antibody reagent, which is utilized for immunohistochemistry.
This new product is designed for the in vitro qualitative detection of the HER2 antigen in breast cancer tissue sections that are embedded in 10% neutral buffered formalin fixed paraffin. It is also intended for the concomitant diagnosis (CDx) of trastuzumab, commercially known as Herceptin. LBP Medicine has also developed a HER2 gene detection kit using the fluorescence in situ hybridization method. With these offerings, LBP Medicine has established itself as the sole domestic company capable of providing a dual-technology detection solution and medication guidance scheme for HER2 in breast cancer pathology.-Fineline Info & Tech
